drugset / Trial / NCT00071708

Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial

NCT00071708

Expanded access Approved for marketing Eli Lilly and Company

Summary

The primary objective of this study is to provide duloxetine to investigators for the treatment of patients who have previously participated in neuroscience duloxetine clinical trials and for whom effective alternative therapy is not available.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 30 mg
Subject Duloxetine Small molecule 120 mg